Although previous reports showed clinicopathological and diagnostic significance of serum p53 antibody in esophageal squamous cell carcinoma, all those reports analyzed only 100 to 200 patients at single institute. This study was designed as a multi-institutional study promoted by the Japan Esophageal Society to elucidate the clinical significance of serum p53 antibody in esophageal cancer treatment. Methods A total of 1,487 patients, from 15 hospitals of Japan, with esophageal carcinoma surgically treated between 2008 and 2016 were enrolled in this retrospective study. We used 1.30 U/ml as a cutoff for classifying patients into positive and negative groups. And we attempted to analyze only positive cases. A receiver operating characteristic curve was constructed to assess serum p53 antibody cutoff levels to differentiate poor prognosis. We used 9.82 U/ml as a cutoff for classifying patients into low and high groups. Univariate and multivariate analyses were used to evaluate the clinicopathological and prognostic significance of pretreatment level of serum p53 antibody. Results There were significant relationships between serum p53 antibody level and tumor depth (p = 0.002), nodal status (p = 0.027) and pathological stage (p = 0.002). The positive serum p53 antibody group had a no significantly worse overall survival than that of the negative group (p = 0.699). The high serum p53 antibody group had a significantly worse overall survival than that of the low group (p = 0.024). However, the difference was not significant in the multivariate analysis (p = 0.137). Conclusion Although high level (>9.82 U/ml) of pretreatment serum p53 antibody might be associated with poor prognosis for patients with esophageal cancer, high serum p53 antibody was not an independent risk factor.

中文翻译：

---

165 1,487 名食管癌患者术前血清 P53 抗体滴度的临床影响：一项多机构研究

虽然以前的报告显示血清 p53 抗体在食管鳞状细胞癌中的临床病理学和诊断意义，但所有这些报告仅分析了单个研究所的 100 至 200 名患者。本研究是日本食管学会推动的一项多机构研究，旨在阐明血清p53抗体在食管癌治疗中的临床意义。方法 2008-2016年间来自日本15家医院接受手术治疗的食管癌患者1487例纳入本回顾性研究。我们使用 1.30 U/ml 作为将患者分为阳性组和阴性组的临界值。我们试图只分析阳性病例。构建受试者工作特征曲线以评估血清 p53 抗体截止水平以区分不良预后。我们用了 9。82 U/ml 作为将患者分为低组和高组的临界值。单变量和多变量分析用于评估预处理血清p53抗体水平的临床病理学和预后意义。结果血清p53抗体水平与肿瘤深度（p = 0.002）、淋巴结状态（p = 0.027）和病理分期（p = 0.002）之间存在显着相关性。血清 p53 抗体阳性组的总生存率没有显着低于阴性组（p = 0.699）。高血清 p53 抗体组的总生存率明显低于低血清组 (p = 0.024)。然而，在多变量分析中差异不显着（p = 0.137）。结论 虽然高水平 (＞9.